RNS Number: 9860Q

GSK PLC 14 July 2025

## **GSK plc (the 'Company')** Transaction notification

Details of PDMR/person closely associated with them ('PCA')				
Name	Er	mma Walmsley		
Position/status	Cł	nief Executive Officer		
Initial notification/ amendment	lni	tial notification		
			arket pa	articipant, auction platform,
Name	G	SK plc		
LEI	54	93000HZTVUYLO1D7	93	
(ii) each type of trans	sa	ction; (iii) each date;		
			pence ea	ach ('Ordinary Shares')
			Shares un	der the Company's Share Reward
Price(s) and volume(s)	)	Price(s)		Volume(s)
		£14.2073		8 (partnership shares)
		£14.2073		8 (matching shares)
Aggregated information				
Date of the transaction	20	25-07-09		
Place of the transaction	Lo	ndon Stock Exchange	(XLON)	
	Position/status  Initial notification/amendment  Details of the issuer auctioneer or auctioner of the transaction(s) has been been been been been been been bee	Position/status Cr Initial notification/ amendment Initial notification/ amendment  Details of the issuer, er auctioneer or auction Initial notification Initial notification Initial	Position/status Chief Executive Officer  Initial notification/ amendment Initial notification  Details of the issuer, emission allowance mactioneer or auction monitor  Name GSK plc  LEI 5493000HZIVUYLO1D79  Details of the transaction(s): section to be refined in the financial instrument of the financial instrument of the transaction (iii) each date; transaction of the financial instrument of Ordinary Section of Ordinary Sectio	Position/status Chief Executive Officer  Initial notification/ amendment Initial notification  Details of the issuer, emission allowance market parauctioneer or auction monitor  Name GSK plc  LEI 5493000HZTVUYLO1D793  Details of the transaction(s): section to be repeated (ii) each type of transaction; (iii) each date; and (iv) transaction(s) has been conducted  Description of the financial instrument Ordinary shares of 31 ¼ pence ex ISIN: GB00BN7SWP63  Nature of the transaction Plan  Price(s) and volume(s) Price(s)  £14.2073  £14.2073  Aggregated information  Aggregated volume Price £14.2073  Date of the transaction 2025-07-09  Place of the London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchang	e (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group Gener	al Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E	793
3.	Details of the transaction (ii) each type of transtransaction(s) has be	saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)		Ordinary shares of 31 ISIN: GB00BN7SWP6	/4 pence each ('Ordinary Shares') 3
b)	Nature of the transaction	Acquisition of Ordinary Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume	18 Ordinary Shares	

Price	£14.2073
Date of the transaction	2025-07-09
Place of the transaction	London Stock Exchange (XLON)
	Date of the transaction Place of the

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communica	ations and CEO Office
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	93
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrumentii) each type of transaction; (iii) each date; and (iv) each place where ransaction(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S Plan	hares under the Company's Share Reward
c)	Price(s) and volume(s	) Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1 ISIN: GB00BN7SWP63	/ <sub>4</sub> pence each ('Ordinary Shares') }
b)	Nature of the transaction	Acquisition of Ordinary Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchang	ge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Suppl	y Chain
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	

	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/pe	rson closely associated	with them ('PCA')
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	3
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	(ii) each type of trai	of the transaction(s): section to be repeated for (i) each type of instrument; type of transaction; (iii) each date; and (iv) each place where ion(s) has been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S Plan	Shares under the Company's Share Reward
c)	Price(s) and volume(s	s) Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange	e (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where		

	transaction(s) has be	en conducted	• •
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S Plan	hares under the Company's Share Reward
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.2073	9 (partnership shares)
		£14.2073	9 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	18 Ordinary Shares £14.2073	
e)	Date of the transaction	2025-07-09	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transac (ii) each type of transaction(s) has be	 saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted	
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary 9 Plan	Shares under the Company's Share Rewa
b)		Plan	Shares under the Company's Share Rewa
,	transaction	Plan	
b)	transaction	Plan Price(s)	Volume(s)
,	transaction	Plan  Price(s) £14.2073	Volume(s) 9 (partnership shares)
c)	transaction  Price(s) and volume(s)  Aggregated	Plan  Price(s) £14.2073	Volume(s) 9 (partnership shares)
c)	transaction  Price(s) and volume(s)  Aggregated information  Aggregated volume	Plan  Price(s) £14.2073 £14.2073	Volume(s) 9 (partnership shares)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Emma Walmsley		
b)	Position/status	Chief Executive Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction	emission allowance market participant, auction platform, n monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where een conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan		
c)	Price(s) and volume(s	Price(s) Volume(s)		
		£14.4447 32		
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2025-07-10		
f)	Place of the transaction	London Stock Exchange (XLON)		

........

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	

b)	transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025 on shares held through the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £14.4447 5
		£ 14.4447
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-07-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Ja	mes Ford	
b)	Position/status	S۱	/P and Group General Counsel,	Legal and Compliance
c)	Initial notification/ amendment	lni	tial notification	
2.	Details of the issuer, auctioneer or auction		mission allowance market pa monitor	rticipant, auction platform,
a)	Name	G	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.		sa	ction; (iii) each date; and (iv)	for (i) each type of instrument; each place where
a)	Description of the financial instrument		dinary shares of 31 ¼ pence ea	ach ('Ordinary Shares')
b)	Nature of the transaction	di۱	equisition of Ordinary Shares fol idends paid to shareholders on rough the Company's Share Rev	10 July 2025 on shares held
c)	Price(s) and volume(s)	)	Price(s)	Volume(s)
			£14.4447	40
				12
d)	Aggregated information	N/	A (single transaction)	12
d)		N/		12
d) e)	information  Aggregated volume			12

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		saction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/2 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction		y Shares following the re-investment o eholders on 10 July 2025 on shares hel Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	21
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange	e (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Office	er
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction		y Shares following the re-investment of eholders on 10 July 2025 on shares held Share Reward Plan
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s)
d)	Aggregated	N/A (single transaction)	

		information	
		Aggregated volume Price	
(	e)	Date of the transaction	2025-07-10
1	f)	Place of the transaction	London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')		
Name	David Redfern	
Position/status	President Corporate	Development
Initial notification/ amendment	Initial notification	
		e market participant, auction platform,
Name	GSK plc	
LEI	5493000HZTVUYLO	1D793
(ii) each type of trans	saction; (iii) each d	be repeated for (i) each type of instrument; ate; and (iv) each place where
Description of the financial instrument		1 ¼ pence each ('Ordinary Shares') 963
transaction	dividends paid to sha	ry Shares following the re-investment of reholders on 10 July 2025 on shares held y's Share Reward Plan
Price(s) and volume(s)	Price(s)	Volume(s)
	£14.4447	84
Aggregated information	N/A (single transacti	on)
Aggregated volume Price		
Date of the transaction	2025-07-10	
Place of the transaction	London Stock Excha	ange (XLON)
	Name  Position/status  Initial notification/ amendment  Details of the issuer, auctioneer or auction  Name  LEI  Details of the transar (ii) each type of trantransaction(s) has been been been been been been been bee	Name    David Redfem

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	

3.	Details of the transac	tion(s): section to be re	peated for (i) each type of instrument		
<b>.</b>	(ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a) Description of the financial instrument		Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	transaction		hares following the re-investment of olders on 10 July 2025 on shares held share Reward Plan		
c)	Price(s) and volume(s)	Price(s) £14.4447	Volume(s) 32		
d)	Aggregated information  Aggregated volume	N/A (single transaction)			
e)	Price Date of the	2025-07-10			
٠,	transaction	-525 51 15			
f)	Place of the transaction	London Stock Exchange	(XLON)		

1.	Details of PDMR/pers	rson closely associated with them ('PCA')				
a)	Name	Ph	ilip Thomson			
b)	Position/status	President, Global Affairs				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio	 , emission allowance market participant, auction platform, on monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted				
		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
a)	Description of the financial instrument			ence eac	h ('Ordinary Shares')	
a) b)		ISI Ac	N: GB00BN7SWP63	ares follo ders on 1	wing the re-investment of 0 July 2025 on shares held	
,	financial instrument  Nature of the	ISI Ac div	N: GB00BN7SWP63  equisition of Ordinary Shidends paid to sharehold	ares follo ders on 1 nare Rewa	wing the re-investment of 0 July 2025 on shares held	
b)	financial instrument  Nature of the transaction	ISI Ac div	N: GB00BN7SWP63 equisition of Ordinary Shidends paid to shareholough the Company's Sh	nares follo ders on 1 nare Rewa	wing the re-investment of 0 July 2025 on shares held ard Plan	
b)	financial instrument  Nature of the transaction	Ac div thr	N: GB00BN7SWP63 equisition of Ordinary Shidends paid to shareholough the Company's Shideness	nares follo ders on 1 nare Rewa	wing the re-investment of 0 July 2025 on shares held ard Plan /olume(s)	
b)	financial instrument  Nature of the transaction  Price(s) and volume(s)  Aggregated	Ac div thr	N: GB00BN7SWP63  equisition of Ordinary Shidends paid to shareholough the Company's Shideness  Price(s)  £14.4447	nares follo ders on 1 nare Rewa	wing the re-investment of 0 July 2025 on shares held ard Plan /olume(s)	
b)	Nature of the transaction  Price(s) and volume(s)  Aggregated information  Aggregated volume	Acdiv thr	N: GB00BN7SWP63  equisition of Ordinary Shidends paid to shareholough the Company's Shideness  Price(s)  £14.4447	nares follo ders on 1 nare Rewa	wing the re-investment of 0 July 2025 on shares held ard Plan /olume(s)	

1.	Details of PDMR/pers	erson closely associated with them ('PCA')				
a)	Name	Deb	oorah Waterhouse			
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auction	the issuer, emission allowance market participant, auction platform, r or auction monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where seen conducted				
a)	Description of the financial instrument		inary shares of 31 ½ I: GB00BN7SWP63	pence ea	ach ('Ordinary Shares')	
b)	Nature of the transaction	divid	quisition of Ordinar dends paid to share ough the Company's	eholders (	s following the re-investment of on 10 July 2025 on shares held ward Plan	
c)	Price(s) and volume(s)	) F	Price(s)		Volume(s)	
		£	£14.4447		70	
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume Price					
e)	Date of the transaction	202	5-07-10			
f)	Place of the transaction	Lon	don Stock Exchange	e (XLON)		

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Victoria Whyte				
b)	Position/status	Company Secretary				
c)	Initial notification/ amendment	Initial notification				
Details of the issuer, emission allowance market participant, auction platfor auctioneer or auction monitor						
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		action(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the	Acquisition of Ordinary Shares following the re-investment of				

-,		dividends paid to shareholders of through the Company's Share Re	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4447	65
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/pe	erson closely associated with them ('PCA')				
a)	Name	Emma Walmsley				
b)	Position/status	Chief Executive Officer				
c)	Initial notification/ amendment	Initial notification				
2.		of the issuer, emission allowance market participant, auction platform, eer or auction monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		nsaction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where			
		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
a)	Description of the financial instrument		pence each ('Ordinary Shares')			
,		ISIN: GB00BN7SWP63  Increase in notional in investment of dividends	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 o			
b)	financial instrument  Nature of the	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 o			
b)	Nature of the transaction	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla			
a) b)	Nature of the transaction	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in (s)  Price(s)	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla			
b)	Nature of the transaction	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in Section (s) Price(s)	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla  Volume(s)  1,708			
b)	Nature of the transaction	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in  (s) Price(s) £14.5450	terest in Ordinary Shares following the respect to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla  Volume(s)  1,708  1,511			
b)	financial instrument  Nature of the transaction  Price(s) and volume(	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in  (s) Price(s) £14.5450	terest in Ordinary Shares following the respect to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla  Volume(s)  1,708  1,511			
b)	Nature of the transaction  Price(s) and volume  Aggregated information  Aggregated volume	ISIN: GB00BN7SWP63  Increase in notional in investment of dividends Ordinary Shares held in (s)  Price(s) £14.5450 £14.5450	terest in Ordinary Shares following the repaid to shareholders on 10 July 2025 of the Company's Deferred Annual Bonus Pla  Volume(s)  1,708  1,511			

a)	Name	Julie Brown				
b)	Position/status	Chief Financial Officer				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auction	r, emission allowance market participant, auction platform, on monitor				
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transa (ii) each type of tran transaction(s) has be	action(s): section to be repeated for (i) each type of instrument; assaction; (iii) each date; and (iv) each place where een conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction	investment of dividend	nterest in Ordinary Shares follow Is paid to shareholders on 10 J In the Company's Deferred Annual	uly 2025 or		
c)	D: ()	Price(s)	Volume(s)			
C)	Price(s) and volume(s)	1	Volume(3)			
C)	Price(s) and volume(s	£14.5450	651			
6)	Price(s) and volume(s		. , ,			
d)	Aggregated information	£14.5450	651			
,	Aggregated	£14.5450	651			
,	Aggregated information  Aggregated volume	£14.5450 £14.5450	651			

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Diana Conrad				
b)	Position/status	Chief People Officer				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the	Increase in notional interest in Ordinary Shares following the re-				

			s paid to shareholders on 10 July 2025 on n the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	169
		£14.5450	275
		£14.5450	430
		L	
d)	Aggregated information		
	- 333	874 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchanç	ge (XLON)

1.	Details of PDMR/pe	ersor	n closely associated	rson closely associated with them ('PCA')			
a)	Name	Ja	mes Ford				
b)	Position/status	S۱	SVP and Group General Counsel, Legal and Compliance				
c)	Initial notification/ amendment	Init	Initial notification				
2.	Details of the issue auctioneer or aucti		, emission allowance market participant, auction platform, on monitor				
a)	Name	GSK plc					
b)	LEI	54	93000HZTVUYLO1D	793			
3.		nsac	ction; (iii) each date	repeated for (i) each type of instrument; e; and (iv) each place where			
		Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
a)	Description of the financial instrument		•				
a) b)		ISI Inc	n: GB00BN7SWP60 crease in notional in estment of dividend	nterest in Ordinary Shares following the rest paid to shareholders on 10 July 2025 or			
b)	financial instrument  Nature of the	Inc inv Or	n: GB00BN7SWP60 crease in notional in estment of dividend	nterest in Ordinary Shares following the rest paid to shareholders on 10 July 2025 or			
b)	Nature of the transaction	Inc inv Or	IN: GB00BN7SWP63 crease in notional in estment of dividend dinary Shares held in	nterest in Ordinary Shares following the rest paid to shareholders on 10 July 2025 or n the Company's Deferred Annual Bonus Plar			
•	Nature of the transaction	Inc inv Or	IN: GB00BN7SWP63 crease in notional in estment of dividend dinary Shares held in Price(s)	nterest in Ordinary Shares following the respect to shareholders on 10 July 2025 or the Company's Deferred Annual Bonus Plar			
b)	Nature of the transaction	Inc inv Or	rease in notional in estment of dividend dinary Shares held in Price(s)	nterest in Ordinary Shares following the respect to shareholders on 10 July 2025 or the Company's Deferred Annual Bonus Plar  Volume(s)  267			
b)	Nature of the transaction	Inc inv Or	rease in notional in estment of dividend dinary Shares held in Price(s) £14.5450	nterest in Ordinary Shares following the respect to shareholders on 10 July 2025 on the Company's Deferred Annual Bonus Plan  Volume(s)  267  436			
b)	financial instrument  Nature of the transaction  Price(s) and volume(	Isi Incinv Or (s)	IN: GB00BN7SWP63 crease in notional in estment of dividend dinary Shares held in Price(s) £14.5450 £14.5450	nterest in Ordinary Shares following the respect to shareholders on 10 July 2025 on the Company's Deferred Annual Bonus Plan  Volume(s)  267  436			
b)	Financial instrument  Nature of the transaction  Price(s) and volume(  Aggregated information  Aggregated volume	Isi Incinv Or (s)	IN: GB00BN7SWP63 crease in notional intestment of dividend dinary Shares held interpreted in the price of the	nterest in Ordinary Shares following the respect to shareholders on 10 July 2025 on the Company's Deferred Annual Bonus Plan  Volume(s)  267  436			

Details of PDMR/per	erson closely associated with them ('PCA')				
Name	Sally Jackson				
Position/status	SVP, Global Communic	ations and CEO Office			
Initial notification/ amendment	Initial notification				
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
Name	GSK plc				
LEI	5493000HZTVUYLO1D793				
(ii) each type of trar	action(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where been conducted				
Description of the financial instrument		4 pence each ('Ordinary Shares')			
Nature of the transaction	investment of dividends	terest in Ordinary Shares following the re- paid to shareholders on 10 July 2025 on the Company's Deferred Annual Bonus Plan			
Price(s) and volume(s	Price(s)	Volume(s)			
	£14.5450	270			
	£14.5450	148			
	£14.5450	166			
Aggregated information					
Aggregated volume Price	584 £14.5450				
Date of the transaction	2025-07-10				
Place of the transaction	London Stock Exchang	e (XLON)			
	Name  Position/status  Initial notification/amendment  Details of the issuer auctioneer or auctionee	Position/status SVP, Global Communication Initial notification amendment Initial notification amendment Details of the issuer, emission allowance rauctioneer or auction monitor  Name GSK plc  LEI 5493000HZTVUYLO1D7  Details of the transaction(s): section to be in (ii) each type of transaction; (iii) each date transaction(s) has been conducted  Description of the financial instrument Increase in notional in investment of dividends Ordinary Shares held in Increase in notional in investment of dividends Ordinary Shares held in Price(s) and volume(s) Price(s)  E14.5450  E14.5450  Aggregated information 584 E14.5450  Date of the transaction 2025-07-10  Place of the London Stock Exchange			

a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, ion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		 action(s): section to be repeated for (i) each type of instrument nsaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)	transaction	nvestment of dividend	interest in Ordinary Shares following th ds paid to shareholders on 10 July 202 in the Company's Deferred Annual Bonus	5 on
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£14.5450	811	
		£14.5450	407	
		£14.5450	644	
d)	Aggregated information			
	33 3	1,862 214.5450		
e)	Date of the transaction	2025-07-10		
f)	Place of the transaction	ondon Stock Exchan	ge (XLON)	
	transaction			-

1.	Details of PDMR/per	son closely associate	ed with them ('PCA')
a)	Name	Shobie Ramakrishnar	1
b)	Position/status	Chief Digital and Tech	nology Officer
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.		saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)	Description of the financial instrument	American Depositary ISIN: US37733W2044	
b)	Nature of the transaction		nterest in ADSs following the re-investment of reholders on 10 July 2025 on ADSs held in the Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		39.5800	131
		39.5800	123
		39.5800	204
n.			
d)	Aggregated information		
	Aggregated volume Price	458 39.5800	
e)	Date of the	2025-07-10	

	transaction	
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/per	son closely associated	d with them ('PCA')
a)	Name	David Redfern	
b)	Position/status	President, Corporate D	evelopment
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each date	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1 ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction	investment of dividend	nterest in Ordinary Shares following the res s paid to shareholders on 10 July 2025 o n the Company's Deferred Annual Bonus Pla
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	372
		£14.5450	516
		£14.5450 £14.5450	235
d)	Aggregated information		
d)			
d) e)	information  Aggregated volume	£14.5450	

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

	Details of the transcrip	-ti(-)ti 4 l	
3.		sactiòn; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ISIN: GB00BN7SWP6	1/4 pence each ('Ordinary Shares') 33
b)		investment of dividen	interest in Ordinary Shares following the re- ds paid to shareholders on 10 July 2025 on in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	345
		£14.5450	622
		£14.5450	299
d)	Aggregated information		
	Aggregated volume Price	1,266 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchar	ige (XLON)

1.	Details of PDMR/per	rson closely associated	d with them ('PCA')
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affair	rs
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction		market participant, auction pla
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	0793
۵,			
3.	(ii) each type of tran transaction(s) has b	nsaction; (iii) each date een conducted	repeated for (i) each type of in e; and (iv) each place where
	(ii) each type of trar	nsaction; (iii) each date een conducted	e; and (iv) each place where  // pence each ('Ordinary Shares')
3.	(ii) each type of transaction(s) has be Description of the	ordinary shares of 31 1 ISIN: GB00BN7SWP63	e; and (iv) each place where  // pence each ('Ordinary Shares')
<b>3.</b>	(ii) each type of transaction(s) has be Description of the financial instrument  Nature of the	ordinary shares of 31 3 ISIN: GB00BN7SWP63 Increase in notional in investment of dividend Ordinary Shares held in	e; and (iv) each place where  // pence each ('Ordinary Shares')  anterest in Ordinary Shares follow by paid to shareholders on 10 Ju
<b>3.</b> a) b)	(ii) each type of transaction(s) has be Description of the financial instrument  Nature of the transaction	ordinary shares of 31 3 ISIN: GB00BN7SWP63 Increase in notional in investment of dividend Ordinary Shares held in	e; and (iv) each place where  // pence each ('Ordinary Shares')  anterest in Ordinary Shares follow the paid to shareholders on 10 Ju in the Company's Deferred Annual
<b>3.</b> a) b)	(ii) each type of transaction(s) has be Description of the financial instrument  Nature of the transaction	Ordinary shares of 31 1 ISIN: GB00BN7SWP63 Increase in notional in investment of dividend Ordinary Shares held in Price(s)	e; and (iv) each place where  // pence each ('Ordinary Shares')  anterest in Ordinary Shares follow as paid to shareholders on 10 Ju an the Company's Deferred Annual  Volume(s)

d)	Aggregated information	
	Aggregated volume Price	751 £14.5450
e)	Date of the transaction	2025-07-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/per	SOI	n closely associated with the	m ('PCA')
a)	Name	De	eborah Waterhouse	
b)	Position/status	CE	EO, ViiV Healthcare and Presid	lent, Global Health, GSK
c)	Initial notification/ amendment	lni	tial notification	
2.	Details of the issuer, auctioneer or auction		mission allowance market pa monitor	articipant, auction platform,
a)	Name	G	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.		sa	ction; (iii) each date; and (iv)	for (i) each type of instrument; each place where
a)	Description of the financial instrument		dinary shares of 31 ¼ pence eans N: GB00BN7SWP63	ach ('Ordinary Shares')
b)	Nature of the transaction	in١	estment of dividends paid to	Ordinary Shares following the re- shareholders on 10 July 2025 on pany's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	)	Price(s)	Volume(s)
			£14.5450	476
			£14.5450	324
			£14.5450	538
d)	Aggregated information			
	Aggregated volume Price		338 4.5450	
e)	Date of the transaction	20	25-07-10	
f)	Place of the transaction	Lc	ndon Stock Exchange (XLON)	

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2	Datalla of the lance	a a considera all accorded manufact manufacture at a continuo mantfacture

۷.	Details of the issuer, auctioneer or auction		market participant, auction piatform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E	7793
3.		saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)		Ordinary shares of 31 ISIN: GB00BN7SWP6	1/4 pence each ('Ordinary Shares') 3
b)	transaction	investment of dividend	nterest in Ordinary Shares following the re is paid to shareholders on 10 July 2025 on the Company's Deferred Annual Bonus Pla
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.5450	662
		£14.5450	302
		£14.5450	226
d)	Aggregated information		
		1,190 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, auctioneer or auction	emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
,		
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where een conducted
	(ii) each type of tran	saction; (iii) each date; and (iv) each place where
3.	(ii) each type of tran transaction(s) has be Description of the	saction; (iii) each date; and (iv) each place where een conducted  Ordinary shares of 31 ½ pence each ('Ordinary Shares')

	I	£14.5450	4,680.094
		£14.5450	5,119.467
d)	Aggregated information Aggregated volume Price	N/A (single tran	saction)
	Price	9,799.561 £14.5450	
e)	Date of the transaction	2025-07-10	
f)	Place of the transaction	London Stock E	Exchange (XLON)

Details of PDMR/per	son closely associa	ated with them ('PCA')
Name	Elizabeth McKee A	nderson
Position/status	Independent Non-E	xecutive Director
Initial notification/ amendment	Initial notification	
		ce market participant, auction platform,
Name	GSK plc	
LEI	5493000HZTVUYLC	01D793
(ii) each type of tran	saction; (iii) each	be repeated for (i) each type of instrument; date; and (iv) each place where
Description of the financial instrument		
Nature of the transaction		s following the re-investment of dividends paid to July 2025
Price(s) and volume(s	Price(s)	Volume(s)
	38.5396	27
Aggregated information	N/A (single transac	tion)
Aggregated volume Price		
Date of the transaction	2025-07-11	
Place of the transaction	New York Stock Ex	change (XNYS)
	Name  Position/status  Initial notification/amendment  Details of the issuer, auctioneer or auctioner or aucti	Position/status Independent Non-Extended Initial notification amendment Initial notification amendment Initial notification amendment Initial notification amendment Initial notification Initial

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification

2.	Details of the issuer, auctioneer or auction		ce market pa	articipant, auction platform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLC	01D793	
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each o		for (i) each type of instrument; each place where
a)	Description of the financial instrument	American Depositar ISIN: US37733W20		Ss')
b)	Nature of the transaction	Acquisition of ADSs shareholders on 10		re-investment of dividends paid to
c)	Price(s) and volume(s)	Price(s) 38.5396		Volume(s) 364
d)	Aggregated information	N/A (single transact	ion)	
	Aggregated volume Price			
e)	Date of the transaction	2025-07-11		
f)	Place of the transaction	New York Stock Ex	change (XNYS	5)
1.	Details of PDMR/per	son closely associa	nted with the	m ('PCA')
a)	Name	Dr Hal Barron		
b)	Position/status	Non-Executive Direc	ctor	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction		ce market pa	articipant, auction platform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLC	)1D793	
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each o		for (i) each type of instrument; each place where
a)	Description of the financial instrument	American Depositar ISIN: US37733W20		Ss')
b)	Nature of the transaction	Acquisition of ADSs shareholders on 10		re-investment of dividends paid to
c)	Price(s) and volume(s	Price(s)		Volume(s)
		38.5396		30
d)	Aggregated information	N/A (single transact	ion)	
	Aggregated volume Price			

(e)	Date of the transaction	2025-07-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/per	rson closely associated with them ('PCA')
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	r, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transa (ii) each type of tran transaction(s) has b	action(s): section to be repeated for (i) each type of instrument; eaction; (iii) each date; and (iv) each place where een conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 July 2025
c)	Price(s) and volume(s	s) Price(s) Volume(s)
		38.5396 35
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-07-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		saction(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where

	transaction(s) has be	en conducted	
a)	Description of the financial instrument	American Depositary ISIN: US37733W204	
b)		Acquisition of ADSs shareholders on 10 J	following the re-investment of dividends paid to luly 2025
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	34
d)	Aggregated information	N/A (single transaction	on)
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exc	change (XNYS)

1.	Details of PDMR/per	son closely associate	d with them ('PCA')	
a)	Name	Dr Jeannie Lee		
b)	Position/status	Independent Non-Exec	cutive Director	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1E	0793	
3.		saction; (iii) each dat	e repeated for (i) each type of instrumer ie; and (iv) each place where	nt;
a)	Description of the financial instrument	American Depositary S ISIN: US37733W2044	Shares ('ADSs')	
b)	Nature of the transaction	Acquisition of ADSs fo shareholders on 10 Jul	ollowing the re-investment of dividends paid ly 2025	to
b)		shareholders on 10 Jul	Volume(s)	to
	transaction	shareholders on 10 Jul	ly 2025	to
	transaction	shareholders on 10 Jul  Price(s)	Volume(s)  11	to
c)	transaction  Price(s) and volume(s  Aggregated	shareholders on 10 Jul  Price(s)  38.5396	Volume(s)  11	to
c)	transaction  Price(s) and volume(s  Aggregated information  Aggregated volume	shareholders on 10 Jul  Price(s)  38.5396	Volume(s)  11	Ito

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr Vishal Sikka	
b)	Position/status	Independent Non-Executiv	e Director
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		rket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	3
3.		saction; (iii) each date; a	peated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	American Depositary Shar ISIN: US37733W2044	res ('ADSs')
b)	Nature of the transaction	Acquisition of ADSs follow shareholders on 10 July 20	ing the re-investment of dividends paid to 025
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		38.5396	103
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	New York Stock Exchange	e (XNYS)

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	David Redfem
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	r, emission allowance market participant, auction platform, ion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		caction(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025, on Ordinary Shares

		neid within an ISA
c)	Price(s) and volume(s)	Price(s) Volume(s) £14.3784 23
d)	Aggregated information  Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-07-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/pers	son closely associated	with them ('PCA')	
a)	Name	Victoria Whyte		
b)	Position/status	Company Secretary		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	l , emission allowance market participant, auction platform, on monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	(ii) each type of tran	of the transaction(s): section to be repeated for (i) each type of instrument; h type of transaction; (iii) each date; and (iv) each place where tion(s) has been conducted		
	transaction(s) has be	een conducted		
a)	` ,		pence each ('Ordinary Shares')	
a) b)	Description of the financial instrument  Nature of the	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S	Shares following the re-investment of	
,	Description of the financial instrument  Nature of the	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S dividends paid to shareh held within an ISA		
b)	Description of the financial instrument  Nature of the transaction	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S dividends paid to shareh held within an ISA	Shares following the re-investment of olders on 10 July 2025, on Ordinary Shares	
b)	Description of the financial instrument  Nature of the transaction  Price(s) and volume(s)	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S dividends paid to shareh held within an ISA  Price(s)	Shares following the re-investment of olders on 10 July 2025, on Ordinary Shares  Volume(s)	
b)	Description of the financial instrument  Nature of the transaction  Price(s) and volume(s)  Aggregated	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S dividends paid to shareh held within an ISA  Price(s) £14.3784	Shares following the re-investment of olders on 10 July 2025, on Ordinary Shares  Volume(s)	
b)	Description of the financial instrument  Nature of the transaction  Price(s) and volume(s)  Aggregated information  Aggregated volume	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Acquisition of Ordinary S dividends paid to shareh held within an ISA  Price(s) £14.3784	Shares following the re-investment of olders on 10 July 2025, on Ordinary Shares  Volume(s)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:mscance">mscance</a> contact <a href="mscance">mscance</a> contact <

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHSFAFLLEISESW